Research
Hormonal
Ketogenic diets are not recommended for patients with Type 1 Diabetes due to increased risks of hypoglycemia, diabetic ketoacidosis (DKA), and potential bone health issues.
Avoid ketogenic diets if you have T1D. The risk of diabetic ketoacidosis (DKA) and hypoglycemia is too high. Focus on balanced meals with nonstarchy vegetables, whole foods, and careful carbohydrate counting instead of extreme restriction.
ModerateRefutesMEDIUM confidence
However, there is not yet sufficient evidence to recommend the safety of a ketogenic diet in T1D, with ongoing concerns for the risk of hypoglycemia, reduced glycogen stores blunting the response to glucagon [38], and the risk of relative insulin deficiency leading to DKA [39].
Why this rating
Based on mechanistic concerns and lack of sufficient safety data, rather than large-scale adverse event trials.
Source
Understanding the Increasing Prevalence of Obesity in Patients With Type 1 Diabetes: Strategies for Improving Clinical Care
Kathleen Ruddiman et al. · Obesity · 2025
DOI 10.1002/oby.70033
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In patients with Type 1 Diabetes (T1D), weight loss interventions reduce insulin requirements but do not significantly improve glycemic control (HbA1c), unlike in Type 2 Diabetes where weight loss directly improves glycemic control.Moderate
- High-intensity interval training (HIIT) is a viable exercise modality for patients with Type 1 Diabetes, offering benefits such as improved quality of life and lower rates of hypoglycemia compared to moderate aerobic exercise.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →